Evidence map›Paper›PMID 37461560›Full record

ArticlebioRxiv : the preprint server for biology2023

Dual targeting of hepatocyte DGAT2 and stellate cell FASN alleviates nonalcoholic steatohepatitis in mice.

Batuhan Yenilmez, Shauna Harney, Chloe DiMarzio, Mark Kelly, Kyounghee Min, Dimas Echeverria, Brianna M Bramato, Samuel O Jackson, Keith Reddig, Jason K Kim and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Batuhan YenilmezProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Shauna HarneyProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Chloe DiMarzioProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Mark KellyProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Kyounghee MinProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Dimas EcheverriaProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Brianna M BramatoProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Samuel O JacksonProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Keith ReddigDepartment of Radiology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Jason K KimProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Anastasia KhvorovaProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Michael P CzechProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
University of Massachusetts Chan Medical School · US

Funding

Paracrine Signaling by Kupffer Cells in Hepatic Insulin ResistanceR01DK103047 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 2015 to 2023
$5.0M
Chemical engineering of therapeutic RNAs for extrahepatic deliveryR35GM131839 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANASTASIA KHVOROVA · 2019 to 2026
$3.1M
Adipocyte to neuron signaling in thermogenic programming of white adipose tissueR01DK116056 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CZECH, MICHAEL P · 2019 to 2023
$2.9M
Transmission Electron Microscope for Core EM FacilityS10OD025113 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HENDRICKS, GREGORY · 2018 to 2018
$600k
Mid-Scale RNA Synthesis, Purification and Quality Control SystemS10OD020012 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KHVOROVA, ANASTASIA · 2015 to 2015
$563k
NIDDK NIH HHS R01 DK103047NIDDK NIH HHS R01 DK116056NIGMS NIH HHS R35 GM131839NIH HHS S10 OD020012NIH HHS S10 OD025113
6 · The paper itself

Abstract

Nonalcoholic steatohepatitis (NASH) is a malady of multiple cell types associated with hepatocyte triglyceride (TG) accumulation, macrophage inflammation, and stellate cell-induced fibrosis, with no approved therapeutics yet available. Here, we report that stellate cell fatty acid synthase (FASN) in de novo lipogenesis drives the autophagic flux that is required for stellate cell activation and fibrotic collagen production. Further, we employ a dual targeting approach to NASH that selectively depletes collagen through selective stellate cell knockout of FASN (using AAV9-LRAT Cre in FASN

Identifiers

PMID37461560
PMCPMC10350091
OpenAlexW4383368861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.